Results 81 to 90 of about 10,491 (187)

Maraviroc and raltegravir [PDF]

British Journal of Clinical Pharmacology, 2009
Eline A, Dubois, Adam F, Cohen
openaire   +2 more sources

High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. [PDF]

, 2014
OBJECTIVES: To analyse the determinants of raltegravir CSF penetration, including the pharmacogenetics of drug transporters located at the blood-brain barrier or blood-CSF barrier.
Audagnotto S, Simiele, Marco, D'Avolio, Antonio, Cusato, Jessica, Bracchi M, Bonora, Stefano, Calcagno, Andrea, Motta, Ilaria, Di Perri, Giovanni   +8 more
core   +1 more source

Budget impact analysis in the maintenance raltegravir-containing regimen in virologically suppressed HIV infected patients

Global & Regional Health Technology Assessment, 2017
Budget impact analysis in the maintenance raltegravir-containing regimen in virologically suppressed HIV infected patientsBackgroundA one-year cost analysis was conducted to estimate the impact from the perspective of the Italian National Health Service (
Roberto Ravasio, Mauro Maresca, Barbara Busà, Benedetto Maurizio Celesia   +3 more
doaj   +1 more source

Micronucleated erythrocytes in newborn rats exposed to raltegravir placental transfer

, 2014
The use of raltegravir in treating HIV/AIDS has been proposed due to its effectiveness in suppressing high loads of HIV RNA in pregnant women, thus preventing infection of the fetus.
Coronado-Medina, D.E., Torres-Mendoza, B.M., Gomez-Meda, B.C., Vazquez-Valls, E., Zamora-Perez, A.L., Zuniga-Gonzalez, G.M., Lemus-Varela, M.D.L.   +6 more
core   +1 more source

A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication [PDF]

, 2014
ObjectivesRecent clinical data have suggested high raltegravir concentrations in gut tissue after oral administration, with implications for treatment and prevention. We have used in silico, in vitro, ex vivo and in vivo models to further investigate the

core   +1 more source

Resistance to inhibitors of the human immunodeficiency virus type 1 integration

Brazilian Journal of Infectious Diseases, 2010
This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 infection.
Daria J. Hazuda, PhD
doaj   +1 more source

Physiologically Based Pharmacokinetic Modelling of UGT Substrate Drugs Lamotrigine and Raltegravir during Pregnancy

Future Pharmacology
Pregnancy is associated with various physiological changes that can significantly impact the disposition of drugs. To further the insight into how pregnancy affects the pharmacokinetics of drugs at different stages, clinical studies can be simulated ...
Monika Berezowska, Paola Coppola, Venkatesh Pilla Reddy, Pradeep Sharma   +3 more
doaj   +1 more source

Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients

, 2016
International audienceOBJECTIVE: We assessed the virological efficacy of a 6 month maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy combining tenofovir disoproxil fumarate/emtricitabine with maraviroc/raltegravir ...
Lucht, Frédéric, Trabaud, Mary-Anne, Brochier, Corinne, Gagnieu, Marie-Claude, Jacomet, Christine, Cottalorda-Dufayard, Jacqueline, Vassallo, Matteo, Cotte, Laurent, Gatey, Caroline, Izopet, Jacques, Raffi, François, Durant, Jacques, Dellamonica, Pierre, Pradat, Pierre   +13 more
core   +1 more source

Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity

European Journal of Medical Research, 2010
Background in HIV-infected patients with HCV-related chronic hepatitis, liver impairment and drug toxicity may substantially reduce the number of possible therapeutic options.
Ortu F, Weimer LE, Floridia M, Manconi PE   +3 more
doaj   +1 more source

Pharmacokinetic drug-drug interaction study between raltegravir and citalopram

, 2016
Contains fulltext : 171175.pdf (Publisher’s version ) (Open Access)BACKGROUND: Depression is the most common mental health disorder among HIV-infected patients.
Schouwenberg, B.J., van Schaik, Ron H. N., Blonk, M.I., Colbers, APH, van Schaik, Ron, Burger, D.M., Langemeijer, Charlotte C. A., Schouwenberg, Bas J. J. W., Colbers, A.P., Hoogtanders, K.E., Hoogtanders, Karin E. J., Colbers, Angela P. H., Blonk, MI, Langemeijer, C.C., Blonk, Maren I., Langemeijer, C C A, Schouwenberg, Bjjw, Schaik, R.H. van, Hoogtanders, K E J   +18 more
core   +1 more source